BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded to Overweight at Morgan Stanley

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) was upgraded by investment analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report released on Monday, The Fly reports.

A number of other equities research analysts also recently issued reports on the company. Truist Financial boosted their price target on BioMarin Pharmaceutical from $125.00 to $135.00 in a research note on Monday, January 10th. StockNews.com assumed coverage on BioMarin Pharmaceutical in a research note on Thursday, March 31st. They set a “hold” rating for the company. Wedbush restated an “outperform” rating and set a $155.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, February 24th. Finally, Piper Sandler boosted their price target on BioMarin Pharmaceutical from $121.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, February 24th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, BioMarin Pharmaceutical has a consensus rating of “Buy” and an average target price of $112.14.

BMRN opened at $80.50 on Monday. The stock has a 50-day moving average price of $80.80 and a 200-day moving average price of $83.30. The company has a debt-to-equity ratio of 0.25, a current ratio of 4.21 and a quick ratio of 2.77. The firm has a market cap of $14.88 billion, a PE ratio of -223.61, a P/E/G ratio of 1.78 and a beta of 0.49. BioMarin Pharmaceutical has a 1 year low of $71.59 and a 1 year high of $94.20.

BioMarin Pharmaceutical (NASDAQ:BMRNGet Rating) last released its quarterly earnings data on Wednesday, February 23rd. The biotechnology company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.01. BioMarin Pharmaceutical had a positive return on equity of 1.32% and a negative net margin of 3.47%. The company had revenue of $449.81 million during the quarter, compared to the consensus estimate of $442.38 million. During the same period last year, the company earned ($0.05) EPS. BioMarin Pharmaceutical’s revenue for the quarter was down .5% on a year-over-year basis. As a group, sell-side analysts anticipate that BioMarin Pharmaceutical will post 0.89 EPS for the current year.

In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock in a transaction dated Thursday, April 14th. The stock was sold at an average price of $83.66, for a total value of $836,600.00. Following the transaction, the chief executive officer now owns 334,983 shares in the company, valued at $28,024,677.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dennis Slamon sold 6,396 shares of BioMarin Pharmaceutical stock in a transaction dated Monday, February 28th. The shares were sold at an average price of $78.33, for a total value of $500,998.68. The disclosure for this sale can be found here. Insiders sold 70,702 shares of company stock worth $5,720,192 in the last quarter. 1.69% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Spire Wealth Management boosted its holdings in BioMarin Pharmaceutical by 59.7% in the fourth quarter. Spire Wealth Management now owns 377 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 141 shares in the last quarter. Ancora Advisors LLC boosted its holdings in BioMarin Pharmaceutical by 466.7% in the third quarter. Ancora Advisors LLC now owns 425 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 350 shares in the last quarter. Liberty Wealth Management LLC boosted its holdings in BioMarin Pharmaceutical by 181.7% in the third quarter. Liberty Wealth Management LLC now owns 431 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 278 shares in the last quarter. CWM LLC lifted its holdings in shares of BioMarin Pharmaceutical by 435.2% during the first quarter. CWM LLC now owns 487 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 396 shares during the period. Finally, Desjardins Global Asset Management Inc. acquired a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth about $53,000. 91.71% of the stock is owned by institutional investors and hedge funds.

BioMarin Pharmaceutical Company Profile (Get Rating)

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Read More

The Fly logo

Analyst Recommendations for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.